TITLE

Insulin Regimens in Type 2 Diabetes

PUB. DATE
December 2009
SOURCE
Travel Medicine Advisor;Dec2009 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the efficacy of insulin in treating type 2 diabetes. It discusses the findings of a study published in the "Journal of the American Medical Association" regarding the use of aldosterone antagonists for the treatment of heart failure (HF). It provides an overview of the Clinical Practice Guidelines published by the American College of Physicians. Moreover, it emphasizes the approval of intravenous (IV) antiviral peramivir by the U.S. Food and Drug Administration (FDA).
ACCESSION #
48667567

 

Related Articles

  • Two new diabetes drugs on the market.  // Cardiology Today;Mar2012, Vol. 15 Issue 3, p35 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of two drugs indicated for the treatment of type 2 diabetes.

  • FDA actions.  // Neurology Alert;Jul2011 Pharmacology Watch, p2 

    The article reports on the actions taken by the U.S. Food and Drug Administration on several drugs including the approval of linagliptin for type 2 diabetes in adults and rilpivirine for adults with HIV-1 and the eventual pulling out of Rosiglitazone (Avandia) from the U.S. market.

  • Amylin's Bydureon NDA Data Held Back, FDA Says. Winter, Peter // BioWorld Today;6/27/2012, Vol. 23 Issue 124, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) requested Amylin Pharmaceuticals for additional information on the cardiovascular effects of Bydureon, a drug for the treatment of type II diabetes. Amylin issued a statement on FDA's agreement to use the data of Byetta, a...

  • FDA OKs 3 Diabetes Drugs.  // Monthly Prescribing Reference;Mar2013, Vol. 29 Issue 3, pA-13 

    The article announces that U.S. Food & Drug Administration has approved three drugs including Nesina (alogliptin), Oseni (alogliptin and pioglitazone), and Kazano (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults.

  • FDA approves updated linagliptin label.  // Endocrine Today;Sep2012, Vol. 10 Issue 9, p10 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of a supplemental drug application for linagliptin tablets for use as an add-on therapy to insulin in patients with type 2 diabetes and for use in patients with type 2 diabetes with severe chronic renal impairment.

  • Colesevelam: A novel drug for comorbid diabetes and dyslipidemia. Dixit, Alok; Pandey, Pinki // Chronicles of Young Scientists;Oct-Dec2012, Vol. 3 Issue 4, p312 

    The article discusses the approval of the colesevelam hydrochloride by the U.S. Food and Drug Administration for type 2 diabetes mellitus and dyslipidemia. It mentions that the drug is approved as adjunctive treatment for T2DM in combination with sulfonylurea, metformin, and insulin therapy. It...

  • New Drug for Type 2 Diabetes.  // Clarendon Enterprise (TX);2/ 7/2013, Vol. 24 Issue 6, p4 

    The article focuses on the new drug Invokana of canagliflozin, which has an approval recommendation from the U.S. Food and Drug Administration (FDA) in treating adult's type 2 diabetes.

  • FDA Approves Janumet XR.  // Chain Drug Review;2/27/2012, Vol. 34 Issue 4, p44 

    The article reports that the U.S. Food and Drug Administration has approved Janumet XR tablets for the treatment of type 2 diabetes.

  • Jardiance OK'd as Type 2 Diabetes Treatment.  // Chain Drug Review;9/29/2014, Vol. 36 Issue 15, p74 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) on the drug Jardiance for the treatment of type 2 diabetes.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics